title: Rituximab and omalizumab in severe, refractory insulin allergy.
authors.forename: Patrick F K
authors.initials: PF
authors.lastname: Yong
authors.forename: Rifat
authors.initials: R
authors.lastname: Malik
authors.forename: Sefina
authors.initials: S
authors.lastname: Arif
authors.forename: Mark
authors.initials: M
authors.lastname: Peakman
authors.forename: Stephanie
authors.initials: S
authors.lastname: Amiel
authors.forename: Mohammad A A
authors.initials: MA
authors.lastname: Ibrahim
authors.forename: Andrew
authors.initials: A
authors.lastname: Gough
mesh_terms: D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy; D003875:Drug Eruptions / Q000188:drug therapy* / Q000209:etiology; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D007155:Immunologic Factors / Q000627:therapeutic use*; D007328:Insulin / Q000009:adverse effects*; D008875:Middle Aged; D000069444:Omalizumab; D000069283:Rituximab
chemical_list: D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D007328:Insulin; D000069444:Omalizumab; D007073:Immunoglobulin E; D000069283:Rituximab